

CASE REPORT

Open Access



Unmasked immune reconstitution inflammatory syndrome towards B-cell non-Hodgkin lymphoma during treatment of esophageal actinomycosis in a patient with advanced HIV: a case report

Elsa K. Vargas-Garcia¹, Augusto R. Fernandez-Aristi¹, Gonzalo Cornejo-Venegas^{1*}, Juan José Montenegro-Idrogo^{2,3,4}, Juan Chirinos-Vega⁶ and Alfredo Chiappe-Gonzalez^{5,6}

Abstract

Background Actinomycosis is an unusual chronic bacterial infection, even rarer in people living with HIV. It is not considered an AIDS-defining disease. However, the role in co-presentation or overlap with other opportunistic conditions of advanced HIV is unknown.

Case presentation A 49-year-old Peruvian male presented with a 4-month history of dysphagia, odynophagia, hyporexia and wasting. He underwent an upper digestive endoscopy, in which ulcers with a necrotic center were observed, therefore, the initial diagnostic assumption was esophageal cancer. Subsequent pathology report excluded neoplasms and confirmed the diagnosis of actinomycosis. Serology for human immunodeficiency virus was requested, yielding a positive result. Antimicrobial treatment with amoxicillin and antiretroviral therapy were indicated, with slow clinical improvement. After 4 months, epigastric discomfort presented, for which a new upper digestive endoscopy was performed, revealing a deep gastric ulcer, which was compatible with diffuse large B-cell non-Hodgkin lymphoma.

Conclusion Esophageal actinomycosis in people living with HIV is very rare. We suggest HIV-associated immunosuppression is not enough to allow for actinomycosis to develop, and masked underlying entities should be sought. The existence of such entities in people living with HIV should raise awareness of the possibility of unmasked immune reconstitution inflammatory syndrome once treatment has started.

Keywords Human immunodeficiency virus, Actinomycosis, Immune reconstitution inflammatory syndrome, Non-Hodgkin lymphoma

*Correspondence:

Gonzalo Cornejo-Venegas
gonza_cornejo@icloud.com

Full list of author information is available at the end of the article



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Introduction

Actinomycosis is a rare subacute-to-chronic infection caused by gram-positive, non-spore forming, non-acid fast, facultative-to-strictly-anaerobic bacilliform bacteria from the genus *Actinomyces* spp. *Actinomyces israelii* is the species that most frequently causes human infections. [1] Because it is an uncommon disease, there are no accurate reports of its incidence, with some series suggesting most large centers may see up to one case per year. [2]

Actinomyces spp. are part of normal flora of human mucosae in the gastrointestinal, respiratory, and genitourinary tract; and only causes disease when there is mucosal barrier breach. As such, common risk factors for actinomycosis include dental and periodontal disease; as well as immunosuppressive states including diabetes mellitus, AIDS and primary immunodeficiencies in children. [3]

Actinomycosis is not a disease usually associated with HIV. However, a brief literature review found esophageal, [4, 5] respiratory, [6] and cutaneous [7] actinomycosis reports in people living with HIV (PLWH). Usually, these reports describe an underlying inflammatory process was present at the time of infection, such as esophageal candidiasis or cytomegalovirus esophagitis.

We report an unusual case of esophageal actinomycosis in a PLWH, that developed a mucosal-associated lymphoid tissue (MALT) lymphoma-associated immune reconstitution inflammatory syndrome (IRIS) after antiretroviral treatment was started.

Case presentation

A 49-year-old male, from Callao, Peru, with a history of untreated arterial hypertension, COVID-19, and bacterial pneumonia two years prior to the current illness presented to the infectious diseases consult with a 4-month history of dysphagia to solids and later to liquids, odynophagia, hyporexia and significant weight loss (22 kg). The physical examination highlighted normal vital functions, a considerable decrease in subcutaneous cell

tissue, onychodystrophy of the feet, scaly erythema on the scalp, and enlarged cervical lymph nodes (the largest at 12 mm). Blood biochemistry showed moderate anemia (Hb 8.1 g/dl) and severe lymphopenia (total lymphocyte count 434 cells/mm³).

An upper digestive endoscopy (UDE) was performed, and a transmural necrotic ulcer with raised nodular edges and a deep bottom with a dark gray base, covering 80% of the circumference was observed. An echoendoscopy was performed, and it was suggestive of stage T3 esophageal neoplasia (Fig. 1).

Pathology reports informed of ulcerated lesions with filiform bacterial colonies in the tissue compatible with esophageal actinomycosis (Fig. 2).

Other infectious agents were excluded by negative staining and cultures, including tuberculosis and fungi. Immunohistochemistry was negative for cytomegalovirus. A chest tomography showed thickening of the distal esophagus, without evidence of enlarged intrathoracic lymph nodes. An abdominal tomography provided no relevant findings. HIV serologic testing was positive, with a viral load of 288 000 copies/ml and CD4+lymphocyte count of 314 cells/ml. The patient was started on oral amoxicillin 500 mg three-times a day; and after two weeks, combined antiretroviral therapy (CART) with a daily combined fixed dose of Tenofovir-disoproxil fumarate/Lamivudine/Dolutegravir 300/300/50 mg was added. Two months later, a new UDE showed that the esophageal ulcer resolved completely, leaving only a residual scar and no relevant findings in the gastric chamber (Fig. 3), with the patient referring remarkable improvement of dysphagia and odynophagia. Similarly, the patient recovered 9 kg of weight in this time.

Four months after the treatment started, the patient returned to the infectious disease outpatient clinic due to a new onset episode of moderate epigastric pain without fever or further symptoms. Blood biochemistry was relevant for moderate anemia (Hb 8.9 g/dl) and lymphopenia (total lymphocyte count 922 cells/mm³). He underwent a new UDE, where a residual esophageal scar was found,




Fig. 1 **A:** gross endoscopical view of the distal third of the esophagus, showing an ulcerative mass with raised edges and active bleeding. **B:** echoendoscopical view of the distal third of the esophagus, showing an infiltrative transmural mass, with fat spiculation




Fig. 2 **A:** endoscopical view of the distal third of the esophagus two months since the beginning of treatment, where resolution of the lesion is seen. **B:** residual scar tissue




Fig. 3 Optical microscopy 20x showing basophilic filamentous bacteria (green arrows), compatible with actinomycosis

as well as a 30 mm ulcer in the gastric corpus, with raised edges and a dirty fibrin bed, friable to rubbing. The pathology and immunohistochemistry of this new gastric lesion were consistent with diffuse large B-cell non-Hodgkin lymphoma with germinal center (Fig. 4).

Unmasking of a previously unknown neoplasia in a patient who had recently started CART was suggestive of IRIS. Currently, the patient receives chemotherapy with the R-CHOP scheme (rituximab, cyclophosphamide, doxorubicin, vincristine and dexamethasone), prophylaxis with trimethoprim/sulfamethoxazole 160/800 mg/day, and continues taking CART and amoxicillin 1.5 g/day with a slow favorable evolution.

Discussion and conclusion

Actinomycosis is a rare disease caused by bacteria from the genus *Actinomyces* spp., which colonizes the gastrointestinal, respiratory, and genitourinary tract as part of normal microbiota. However, chronic injury of a colonized area may lead to disease. [1, 3, 8] Cases have been described in PLWH and most reports describe lymphocyte T CD4<200 cell/mL. [4–7] Furthermore, reports usually highlight underlying conditions which accompany the diagnosis of esophageal actinomycosis, such as esophageal candidiasis, cytomegalovirus esophagitis or neoplasia.

Esophageal actinomycosis does not usually involve the distal third of the esophagus due to its distance from the oropharynx, [9] but can present as chronic esophageal




Fig. 4 Optical microscopy 20x showing reactive follicles with neoplastic cells invading the marginal zone

ulceration [10, 11] or even mimicking esophageal carcinoma, [12–15] as in our case. Neurological dysphagia leading to aspiration constitutes a further risk factor that has been reported in some cases and is associated with distal esophageal compromise. [10, 11, 15] In the case we describe, probably both the digestive mucosa MALT-lymphoma-associated changes as well as HIV-associated immunosuppression led to the development of esophageal actinomycosis.

Clinical manifestations of esophageal actinomycosis range from dyspepsia and dysphagia to weight loss and wasting, mimicking the clinical presentation of a neoplasm. [16] While our patient had dysphagia, but was able to eat and drink, and had a CD4+T lymphocyte count greater than 200 cells/ml, it is possible that the actinomycosis alone did not account for the wasting syndrome and therefore, further studies to explain emaciation were justified. Even though HIV infection could justify the weight loss, the not so low CD4+T lymphocyte count (314 cells/ml) strongly leads us to believe that this was the result of underlying neoplasm.

Actinomycosis shows a good clinical response to long courses of amoxicillin, penicillin G, doxycycline, or metronidazole, ranging from 6 to 12 months. [7] Such is the case of this patient, whose mass resolved leaving only a well healing scar without any evidence of strictures and resolution of all initial symptoms.

This patient presented HIV-associated immunosuppression [1, 4] as the only risk factor for invasive actinomycosis. Nevertheless, it has been reported that PLWH may present actinomycosis with CD4 cell counts as

high as 300 cells/mL. [6, 17, 18] Other small studies in patients with invasive actinomycosis showed that it is a surrogate marker of poor prognosis in this specific vulnerable hosts. [19] Despite our patient had an initial CD4 count of 314 cells/ml, due to immunosuppression stigma and presence of neoplasm, we considered him to be in an advanced stage of HIV.

Proper CART naive-treatment was started with the combine dose formulation of Tenofovir-DF/Lamivudine/Dolutegravir. After 12 weeks of treatment, he reached a viral load of 164 copies/ml. Even though recurrence of invasive actinomycosis is extremely rare, [20] presence of immunocompromised state such as untreated HIV infection; puts patients increased risk of recurrence especially if the CART is inconsistent. Our case did not present recurrent actinomycosis because there was clinical and structural resolution of esophageal ulcers. In the context of viral control with appearance of new symptoms, it's reasonable to consider other opportunistic infections. The UDS showed one new gastric lesion compatible with unmasked non-Hodgkin lymphoma-associated IRIS after CART and actinomycosis treatment.

In conclusion, despite its unusual occurrence, esophageal actinomycosis in PLWH in an advanced stage should arise suspicion for further opportunistic conditions that overlap or hide the clinical manifestations. PLWH and actinomycosis should be strictly monitored until viral control is achieved, and antibiotic courses are completed.

Abbreviations

HIV	Human immunodeficiency virus
PLWH	persons living with HIV

ART	Antiretroviral therapy
R-CHOP	chemotherapy scheme based in rituximab, cyclophosphamide, doxorubicin hydrochloride (hydroxydaunorubicin), vincristine sulfate (Oncovin), and prednisone
IRIS	immune reconstitution inflammatory syndrome
Hb	hemoglobin
PCR	Polymerase chain reaction

Acknowledgements

We express our gratitude to all the medical staff involved in the management of the patient in this case.

Authors' contributions

Elsa K. Vargas-Garcia is the first author who contributed to the writing of the paper and performed the analysis. Gonzalo Cornejo-Venegas is the author for correspondence and contributed to the study design, analysis, data collection, and writing of the paper. Augusto R. Fernandez-Aristi, Juan José Montenegro-Idrogo, Juan Chirinos-Vega and Alfredo Chiappe-Gonzalez contributed to the design and analysis as well as the article review. R. Fernandez-Aristi provided technical assistance and performed data collection. Juan Chirinos-Vega and Alfredo Chiappe-Gonzalez contributed to the data review and manuscript revision. All authors read and approved the final manuscript.

Funding

This research was self-financed.

Data Availability

The data that support the findings of this study are openly available.

Declarations

Competing interests

The authors declare no competing interests.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Written informed consent for publication of their clinical details and/or clinical images was obtained from the patient. A copy of the consent form is available for review by the Editor of this journal.

Author details

¹Universidad Peruana de Ciencias Aplicadas, Avenida Alameda San Marcos cuadra 2 S/N, Chorrillos, Lima 15023, Peru

²Hospital Nacional Dos de Mayo. Parque "Historia de la Medicina Peruana" S/N, Lima 15003, Peru

³Facultad de Ciencias de la Salud, Universidad Científica del Sur. Carretera Panamericana, Sur km19, Villa El Salvador, Lima 15067, Peru

⁴Centro de Investigaciones Tecnológicas, Biomédicas y Medioambientales, Universidad Nacional Mayor de San Marcos, Lima 070102, Peru

⁵Instituto de Investigaciones en Ciencias Biomédicas, Universidad Ricardo Palma, Lima, Peru

⁶Clinica Angloamericana, Calle Alfredo Salazar 350, Lima, San Isidro 15073, Peru

Received: 27 April 2023 / Accepted: 13 May 2023

Published online: 14 July 2023

References

1. Valour F, Sénéchal A, Dupieux C, et al. Actinomycosis: etiology, clinical features, diagnosis, treatment, and management. *Infect Drug Resist.* 2014;7:183–97.
2. Belmont MJ, Behar PM, Wax MK. Atypical presentations of actinomycosis. *Head Neck.* 1999;21(3):264–8.
3. Sharma S, Hashmi MF, Valentino DJ III. Actinomycosis. [Updated 2022 Aug 18]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK482151/>.
4. Maquera-Afaray J, Pérez-Lazo G, Magallanes J, Arenas J. Actinomicosis esofágica en pacientes con infección por VIH [Esophageal actinomycosis in patients with HIV infection]. *Rev Gastroenterol Peru.* 2019;39(2):160–3.
5. Lee SA, Palmer GW, Cooney EL. Esophageal actinomycosis in a patient with AIDS. *Yale J Biol Med.* 2001;74(6):383–9.
6. Park JW, Kim YH, Lee E, Park SY, Kim TH. Actinomycosis presenting as an isolated pleural effusion in a patient with an HIV infection: a case report and literature review. *AIDS Res Ther.* 2021;18(1):86. <https://doi.org/10.1186/s12981-021-00412-5>. Published 2021 Nov 17.
7. Khadka P, Koirala S. Primary cutaneous actinomycosis: a diagnosis consideration in people living with HIV/AIDS. *AIDS Res Ther.* 2019;16:16. <https://doi.org/10.1186/s12981-019-0232-4>.
8. Urbán E, Gajdács M. Microbiological and clinical aspects of Actinomycetes infections: what have we learned? *Antibiot (Basel).* 2021;10(2):151. <https://doi.org/10.3390/antibiotics10020151>. Published 2021 Feb 3.
9. Könönen E, Wade WG. Actinomycetes and related organisms in human infections. *Clin Microbiol Rev.* 2015;28(2):419–42. <https://doi.org/10.1128/CMR.00100-14>.
10. Thota PN, Liu X, Sanaka MR. Dysphagia caused by esophageal actinomycosis. *Clin Gastroenterol Hepatol.* 2015;13(6):A21–2. <https://doi.org/10.1016/j.cgh.2015.01.012>.
11. Pillappa R, O'Brien T, Sullivan J, Weksler B. Esophageal Actinomycoses mimicking malignancy. *Ann Thorac Surg.* 2016 May;101(5):1967–70.
12. Deswysen Y, Van Ginderachter L, Dano H, Belkhir L. Mimicking oesophageal cancer: oesophageal actinomycosis. *Lancet Infect Dis.* 2019;19(5):558. [https://doi.org/10.1016/S1473-3099\(18\)30740-0](https://doi.org/10.1016/S1473-3099(18)30740-0).
13. Alshati A, Appleton L, Maddux JT, Almohammedawi M, Dangerfield B. Esophageal actinomycosis presenting as an obstructive esophageal Mass. *ACG Case Rep J.* 2019;6(7):e00140. <https://doi.org/10.14309/crj.00000000000000140>. Published 2019 Jul 23.
14. Ruiz Rebollo ML, González Obeso E, Burgueño Gómez B, Santos Fernández J. Esophageal actinomycosis mimicking a carcinoma. *Rev Esp Enferm Dig.* 2020;112(3):234–5. <https://doi.org/10.17235/reed.2020.6053/2018>.
15. Li J, Li Y, Zhou Y, Wang C, Wu B, Wan J. *Actinomycetes and Alimentary Tract Diseases: A Review of Its Biological Functions and Pathology. Biomed Res Int.* 2018;2018:3820215. Published 2018 Aug 26. doi:<https://doi.org/10.1155/2018/3820215>.
16. Codipilly DC, Wang KK. Squamous cell carcinoma of the Esophagus. *Gastroenterol Clin North Am.* 2022;51(3):457–84. <https://doi.org/10.1016/j.gtc.2022.06.005>.
17. Murchan EM, Redelman-Sidi G, Patel M, Dimaio C, Seo SK. Esophageal actinomycosis in a fifty-three-year-old man with HIV: case report and review of the literature. *AIDS Patient Care STDS.* 2010;24(2):73–8. <https://doi.org/10.1089/apc.2009.0185>.
18. Gomes J, Pereira T, Carvalho A, Brito C. Primary cutaneous actinomycosis caused by *Actinomyces meyeri* as first manifestation of HIV infection. *Dermatol Online J.* 2011;17(11):5. Published 2011 Nov 15.
19. Pierre I, Zarrouk V, Noussair L, Molina JM, Fantin B. Invasive actinomycosis: surrogate marker of a poor prognosis in immunocompromised patients. *Int J Infect Dis.* 2014;29:74–9. <https://doi.org/10.1016/j.ijid.2014.06.012>.
20. Boot M, Archer J, Ali I. The diagnosis and management of pulmonary actinomycosis [published online ahead of print, 2023 Feb 8]. *J Infect Public Health.* 2023;16(4):490–500. <https://doi.org/10.1016/j.jiph.2023.02.004>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.